Researchers associated with SEngine Precision Medicine, a precision oncology company that matches patients to medicines based on their own tumor samples, have published a new case report showing a patient's remarkable response to an off-label therapy identified by its PARIS Test. Despite standard-of-care chemotherapy and two surgeries, the patient's low-grade serous ovarian cancer (LGSOC) was progressing and her prognosis was terminal. But by testing a range of therapies in organoids grown from the patient's own tumor sample, SEngine's PARIS Test identified as a top candidate ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas and with no prior...